参考文献

1.Siegel RL，Miller KD，Jemal A.Cancer Statistics，2017.CA Cancer JClin，2017，67（1）：7-30.

2.Jung KW，Won YJ，Kong HJ，et al.Cancer statistics in Korea：incidence，mortality，survival，and prevalence in 2012.Cancer Res Treat，2015，47（2）：127-141.

3.Lim H，Devesa SS，Sosa JA，et al.Trends in Thyroid Cancer Incidence and Mortality in the United States，1974-2013.JAMA，2017，317（13）：1338-1348.

4.Parkin DM，Bray F，Ferlay J，et al.Global cancer statistics，2002.CA Cancer JClin，2005，55（2）：74-108.

5.Chen AY，Jemal A，Ward EM.Increasing incidence of differentiated thyroid cancer in the United States，1988-2005.Cancer，2009，115（16）：3801-3807.

6.Cramer JD，Fu P，Harth KC，et al.Analysis of the rising incidence of thyroid cancer using the Surveillance，Epidemiology and End Results national cancer data registry.Surgery，2010，148（6）：1147-1152；discussion 1152-1143.

7.Enewold L，Zhu K，Ron E，et al.Rising thyroid cancer incidence in the United States by demographic and tumor characteristics，1980-2005.Cancer Epidemiol Biomarkers Prev，2009，18（3）：784-791.

8.Morris LG，Myssiorek D.Improved detection does not fully explain the rising incidence of well-differentiated thyroid cancer：a population-based analysis.Am J Surg，2010，200（4）：454-461.

9.Davies L，Welch HG.Increasing incidence of thyroid cancer in the United States，1973-2002.JAMA，2006，295（18）：2164-2167.

10.Olaleye O，Ekrikpo U，Moorthy R，etal.Increasing incidence of differentiated thyroid cancer in South East England：1987-2006.Eur Arch Otorhinolaryngol，2011，268（6）：899-906.

11.Hall SF，Walker H，Siemens R，et al.Increasing detection and increasing incidence in thyroid cancer.World J Surg，2009，33（12）：2567-2571.

12.Colonna M，Guizard AV，Schvartz C，et al.A time trend analysis of papillary and follicular cancers as a function of tumour size：a study of data from six cancer registries in France（1983-2000）.Eur JCancer，2007，43（5）：891-900.

13.Uhry Z，Colonna M，Remontet L，et al.Estimating infra-national and national thyroid cancer incidence in France from cancer registries data and national hospital discharge database.Eur JEpidemiol，2007，22（9）：607-614.

14.Burgess JR.Temporal trends for thyroid carcinoma in Australia：an increasing incidence of papillary thyroid carcinoma（1982-1997）.Thyroid，2002，12（2）：141-149.

15.Capezzone M，Morabito E，Bellitti P，et al.Increasing incidence of thyroid cancer in Basilicata：an Italian study.JEndocrinol Invest，2007，30（6）：507-512.

16.Smailyte G，Miseikyte-Kaubriene E，Kurtinaitis J.Increasing thyroid cancer incidence in Lithuania in 1978-2003.BMC Cancer，2006，6.284.

17.He Y，Liang D，Li D，et al.Estimated cancer incidence and mortality in Hebei province，2012.Chin JCancer Res，2016，28（3）：286-300.

18.Fu Z，Lu Z，Li Y，et al.Cancer incidence and mortality in Shandong province，2012.Chin JCancer Res，2016，28（3）：263-274.

19.Liu S，Chen Q，Quan P，et al.Cancer incidence and mortality in Henan province，2012.Chin JCancer Res，2016，28（3）：275-285.

20.Liu Y，Zhang X，Chen L，et al.Cancer incidence andmortality in Gansu province，2012.Chin J Cancer Res，2016，28（3）：301-310.

21.Chen W，Zheng R，Baade PD，et al.Cancer statistics in China，2015.CA Cancer JClin，2016，66（2）：115-132.

22.Manolio TA，Bailey-Wilson JE，Collins FS.Genes，environment and the value of prospective cohort studies.Nat Rev Genet，2006，7（10）：812-820.

23.Li L，Lyu J.[Large prospective cohort studies：a review and update].Zhonghua Liu Xing Bing Xue Za Zhi，2015，36（11）：1187-1189.

24.Cardis E，Howe G，Ron E，et al.Cancer consequences of the Chernobyl accident：20 years on.J Radiol Prot，2006，26（2）：127-140.

25.Williams D.Radiation carcinogenesis：lessons from Chernobyl.Oncogene，2008，27 Suppl 2.S9-18.

26.Veiga LH，Lubin JH，Anderson H，etal.A pooled analysis of thyroid cancer incidence following radiotherapy for childhood cancer.Radiat Res，2012，178（4）：365-376.

27.Wang JX，Zhang LA，Li BX，et al.Cancer incidence and risk estimation among medical x-ray workers in China，1950-1995.Health Phys，2002，82（4）：455-466.

28.Wingren G，Hallquist A，Hardell L.Diagnostic X-ray exposure and female papillary thyroid cancer：a pooled analysis of two Swedish studies.Eur J Cancer Prev，1997，6（6）：550-556.

29.Zhang Y，Chen Y，Huang H，et al.Diagnostic radiography exposure increases the risk for thyroid microcarcinoma：a population-based case-control study.Eur J Cancer Prev，2015，24（5）：439-446.

30.Dal Maso L，Bosetti C，La Vecchia C，et al.Risk factors for thyroid cancer：an epidemiological review focused on nutritional factors.Cancer Causes Control，2009，20（1）：75-86.

31.Negri E，Ron E，Franceschi S，et al.A pooled analysis of case-control studies of thyroid cancer.I Methods.Cancer Causes Control，1999，10（2）：131-142.

32.Bianco AC，Anderson G，Forrest D，et al.American Thyroid Association Guide to investigating thyroid hormone economy and action in rodentand cellmodels.Thyroid，2014，24（1）：88-168.

33.Knobel M，Medeiros-Neto G.Relevance of iodine intake as a reputed predisposing factor for thyroid cancer.Arq Bras Endocrinol Metabol，2007，51（5）：701-712.

34.Sohn SY，Choi JY，Jang HW，et al.Association between excessive urinary iodine excretion and failure of radioactive iodine thyroid ablation in patients with papillary thyroid cancer.Thyroid，2013，23（6）：741-747.

35.Xu L，PortM，Landi S，etal.Obesity and the risk of papillary thyroid cancer：a pooled analysis of three case-control studies.Thyroid，2014，24（6）：966-974.

36.Bhaskaran K，Douglas I，Forbes H，et al.Body-mass index and risk of 22 specific cancers：a population-based cohort study of 5.24million UK adults.Lancet，2014，384（9945）：755-765.

37.Renehan AG，Tyson M，Egger M，et al.Body-mass index and incidence of cancer：a systematic review and meta-analysis of prospective observational studies.Lancet，2008，371（9612）：569-578.

38.Pappa T，AlevizakiM.Obesity and thyroid cancer：a clinical update.Thyroid，2014，24（2）：190-199.

39.Cho YA，Kim J.Thyroid cancer risk and smoking status：a meta-analysis.Cancer Causes Control，2014，25（9）：1187-1195.

40.Soldin OP，Goughenour BE，Gilbert SZ，et al.Thyroid hormone levels associated with active and passive cigarette smoking.Thyroid，2009，19（8）：817-823.

41.Brand JS，Chan MF，DowsettM，et al.Cigarette smoking and endogenous sex hormones in postmenopausal women.JClin Endocrinol Metab，2011，96（10）：3184-3192.

42.Hong SH，Myung SK，Kim HS，et al.Alcohol Intake and Risk of Thyroid Cancer：A Meta-Analysis of Observational Studies.Cancer Res Treat，2017，49（2）：534-547.

43.Boelaert K.The association between serum TSH concentration and thyroid cancer.Endocr Relat Cancer，2009，16（4）：1065-1072.

44.Knudsen N，Bulow I，Laurberg P，et al.Alcohol consumption is associated with reduced prevalence of goitre and solitary thyroid nodules.Clin Endocrinol（Oxf），2001，55（1）：41-46.

45.Costa LG，de Laat R，Tagliaferri S，et al.A mechanistic view of polybrominated diphenyl ether（PBDE）developmental neurotoxicity.Toxicol Lett，2014，230（2）：282-294.

46.Zhang Y，Guo GL，Han X，et al.Do Polybrominated Diphenyl Ethers（PBDEs）Increase the Risk of Thyroid Cancer？Biosci Hypotheses，2008，1（4）：195-199.

47.Aschebrook-Kilfoy B，DellaValle CT，Purdue M，et al.Polybrominated diphenyl ethers and thyroid cancer risk in the Prostate，Colorectal，Lung，and Ovarian Cancer Screening Trial cohort.Am JEpidemiol，2015，181（11）：883-888.

48.Van der Ven LT，van de Kuil T，Leonards PE，et al.A 28-day oral dose toxicity study in Wistar rats enhanced to detect endocrine effects of decabromodiphenyl ether（decaBDE）.Toxicol Lett，2008，179（1）：6-14.

49.Ernest SR，Wade MG，Lalancette C，et al.Effects of chronic exposure to an environmentally relevant mixture of brominated flame retardants on the reproductive and thyroid system in adultmale rats.Toxicol Sci，2012，127（2）：496-507.

50.Mooney SJ，Westreich DJ，El-Sayed AM.Commentary：Epidemiology in the era of big data.Epidemiology，2015，26（3）：390-394.

51.Nilubol N，Kebebew E.Should small papillary thyroid cancer be observed？A population-based study.Cancer，2015，121（7）：1017-1024.

52.Haugen BR，Alexander EK，Bible KC，et al.2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer：The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.Thyroid，2016，26（1）：1-133.

53.Perera FP，Weinstein IB.Molecular epidemiology and carcinogen-DNA adduct detection：new approaches to studies of human cancer causation.J Chronic Dis，1982.35（7）：581-600.

54.Walsh T，King MC.Ten genes for inherited breast cancer.Cancer Cell，2007，11（2）：103-105.

55.Bastos HN，Antao MR，Silva SN，et al.Association of polymorphisms in genes of the homologous recombination DNA repair pathway and thyroid cancer risk.Thyroid，2009，19（10）：1067-1075.

56.Sturgis EM，Zhao C，Zheng R，et al.Radiation response genotype and risk of differentiated thyroid cancer：a case-control analysis.Laryngoscope，2005，115（6）：938-945.

57.Yuan K，Huo M，Sun Y，et al.Association between x-ray repair cross-complementing group 3（XRCC3）genetic polymorphisms and papillary thyroid cancer susceptibility in a Chinese Han population.Tumour Biol，2016，37（1）：979-987.

58.Rahimi M，Fayaz S，Fard-Esfahani A，et al.The role of Ile3434Thr XRCC7 gene polymorphism in differentiated thyroid cancer risk in an Iranian population.Iran Biomed J，2012，16（4）：218-222.

59.Ryu RA，Tae K，Min HJ，et al.XRCC1 polymorphisms and risk of papillary thyroid carcinoma in a Korean sample.J Korean Med Sci，2011，26（8）：991-995.

60.Chiang FY，Wu CW，Hsiao PJ，et al.Association between polymorphisms in DNA base excision repair genes XRCC1，APE1，and ADPRT and differentiated thyroid carcinoma.Clin Cancer Res，2008，14（18）：5919-5924.

61.Zhu QX，Bian JC，Shen Q，et al.[Genetic polymorphisms in X-ray repair cross-complementing gene 1 and susceptibility to papillary thyroid carcinoma].Zhonghua Liu Xing Bing Xue Za Zhi，2004，25（8）：702-705.

62.Sunaga N，Kohno T，Yanagitani N，et al.Contribution of the NQO1 and GSTT1 polymorphisms to lung adenocarcinoma susceptibility.Cancer Epidemiol Biomarkers Prev，2002，11（8）：730-738.

63.Tebbs RS，Zhao Y，Tucker JD，et al.Correction of chromosomal instability and sensitivity to diverse mutagens by a cloned cDNA of the XRCC3 DNA repair gene.Proc Natl Acad Sci U SA，1995，92（14）：6354-6358.

64.Siraj AK，Ibrahim M，Al-Rasheed M，et al.Polymorphisms of selected xenobiotic genes contribute to the development of papillary thyroid cancer susceptibility in Middle Eastern population.BMCMed Genet，2008，9.61.

65.Prasad VV，Wilkhoo H.Association of the functional polymorphism C677T in themethylenetetrahydrofolate reductase gene with colorectal，thyroid，breast，ovarian，and cervical cancers.Onkologie，2011，34（8-9）：422-426.

66.Fard-Esfahani P，Fard-Esfahani A，Saidi P，et al.An increased risk of differentiated thyroid carcinoma in Iran with the 677C--＞T homozygous polymorphism in the MTHFR Gene.Cancer Epidemiol，2011，35（1）：56-58.

67.Ozdemir S，Silan F，Hasbek Z，et al.Increased T-allele frequency of 677 C＞T polymorphism in the methylenetetrahydrofolate reductase gene in differentiated thyroid carcinoma.Genet TestMol Biomarkers，2012，16（7）：780-784.

68.Barbieri RB，Bufalo NE，Cunha LL，et al.Genes of detoxification are importantmodulators of hereditarymedullary thyroid carcinoma risk.Clin Endocrinol（Oxf），2013，79（2）：288-293.

69.BarbieriRB，Bufalo NE，Secolin R，etal.Evidence that polymorphisms in detoxification genes modulate the susceptibility for sporadicmedullary thyroid carcinoma.Eur JEndocrinol，2012，166（2）：241-245.

70.Reis AA，Silva DM，Curado MP，et al.Involvement of CYP1A1，GST，72TP53 polymorphisms in the pathogenesis of thyroid nodules.GenetMol Res，2010，9（4）：2222-2229.

71.Akulevich NM，Saenko VA，Rogounovitch TI，etal.Polymorphisms of DNA damage response genes in radiation-related and sporadic papillary thyroid carcinoma.Endocr Relat Cancer，2009，16（2）：491-503.

72.Siraj AK，Al-Rasheed M，Ibrahim M，et al.RAD52 polymorphisms contribute to the development of papillary thyroid cancer susceptibility in Middle Eastern population.JEndocrinol Invest，2008，31（10）：893-899.

73.Bufalo NE，Leite JL，Guilhen AC，etal.Smoking and susceptibility to thyroid cancer：an inverse association with CYP1A1 allelic variants.Endocr Relat Cancer，2006，13（4）：1185-1193.

74.Rogounovitch TI，Saenko VA，Ashizawa K，et al.TP53 codon 72 polymorphism in radiation-associated human papillary thyroid cancer.Oncol Rep，2006，15（4）：949-956.

75.Granja F，Morari J，Morari EC，et al.Proline homozygosity in codon 72 of p53 is a factor of susceptibility for thyroid cancer.Cancer Lett，2004，210（2）：151-157.

76.Boltze C，Roessner A，Landt O，et al.Homozygous proline at codon 72 of p53 as a potential risk factor favoring the development of undifferentiated thyroid carcinoma.Int JOncol，2002，21（5）：1151-1154.

77.McCarthy MI，Abecasis GR，Cardon LR，et al.Genome-wide association studies for complex traits：consensus，uncertainty and challenges.Nat Rev Genet，2008，9（5）：356-369.

78.Figlioli G，Kohler A，Chen B，et al.Novel genome-wide association study-based candidate loci for differentiated thyroid cancer risk.JClin Endocrinol Metab，2014，99（10）：E2084-2092.

79.Kohler A，Chen B，Gemignani F，et al.Genome-wide association study on differentiated thyroid cancer.JClin Endocrinol Metab，2013，98（10）：E1674-1681.

80.Mancikova V，Cruz R，Inglada-Perez L，et al.Thyroid cancer GWAS identifies 10q26.12 and 6q14.1 as novel susceptibility loci and reveals genetic heterogeneity among populations.Int JCancer，2015，137（8）：1870-1878.

81.Gudmundsson J，Thorleifsson G，Sigurdsson JK，et al.A genome-wide association study yields five novel thyroid cancer risk loci.Nat Commun，2017，8：14517.

82.Son HY，Hwangbo Y，Yoo SK，et al.Genome-wide association and expression quantitative trait loci studies identifymultiple susceptibility loci for thyroid cancer.Nat Commun，2017，8：15966.

83.Liyanarachchi S，Wojcicka A，Li W，et al.Cumulative risk impact of five genetic variants associated with papillary thyroid carcinoma.Thyroid，2013，23（12）：1532-1540.

84.Gudmundsson J，Sulem P，Gudbjartsson DF，et al.Common variants on 9q22.33 and 14q13.3 predispose to thyroid cancer in European populations.Nat Genet，2009，41（4）：460-464.

85.Omur O，Baran Y.An update on molecular biology of thyroid cancers.Crit Rev Oncol Hematol，2014，90（3）：233-252.

86.Garnett MJ，Marais R.Guilty as charged：B-RAF is a human oncogene.Cancer Cell，2004，6（4）：313-319.

87.Smith N，Nucera C.Personalized therapy in patientswith anaplastic thyroid cancer：targeting genetic and epigenetic alterations.JClin Endocrinol Metab，2015，100（1）：35-42.

88.Flaherty KT，Robert C，Hersey P，et al.Improved survival with MEK inhibition in BRAF-mutated melanoma.N Engl J Med，2012，367（2）：107-114.

89.Kim TH，Park YJ，Lim JA，et al.The association of the BRAF（V600E）mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer：a meta-analysis.Cancer，2012，118（7）：1764-1773.

90.Trovisco V，Soares P，Preto A，et al.Type and prevalence of BRAF mutations are closely associated with papillary thyroid carcinoma histotype and patients′age but not with tumour aggressiveness.Virchows Arch，2005，446（6）：589-595.

91.Fallahi P，Ferrari SM，Santini F，et al.Sorafenib and thyroid cancer.BioDrugs，2013，27（6）：615-628.

92.Alonso-Gordoa T，Diez JJ，Duran M，et al.Advances in thyroid cancer treatment：latest evidence and clinical potential.Ther Adv Med Oncol，2015，7（1）：22-38.

93.Hsiao SJ，Nikiforov YE.Molecular approaches to thyroid cancer diagnosis.Endocr Relat Cancer，2014，21（5）：T301-313.

94.Hamatani K，Eguchi H，Ito R，et al.RET/PTC rearrangements preferentially occurred in papillary thyroid cancer among atomic bomb survivors exposed to high radiation dose.Cancer Res，2008，68（17）：7176-7182.

95.Wang YL，Zhang RM，Luo ZW，etal.High frequency of level II-V lymph node involvement in RET/PTC positive papillary thyroid carcinoma.Eur JSurg Oncol，2008，34（1）：77-81.

96.Borrello MG，Ardini E，Locati LD，et al.RET inhibition：implications in cancer therapy.Expert Opin Ther Targets，2013，17（4）：403-419.

97.Sadow PM，Heinrich MC，Corless CL，et al.Absence of BRAF，NRAS，KRAS，HRAS mutations，and RET/PTC gene rearrangements distinguishes dominantnodules in Hashimoto thyroiditis from papillary thyroid carcinomas.Endocr Pathol，2010，21（2）：73-79.

98.Fukahori M，Yoshida A，Hayashi H，et al.The associations between RAS mutations and clinical characteristics in follicular thyroid tumors：new insights from a single center and a large patient cohort.Thyroid，2012，22（7）：683-689.

99.Kroll TG，Sarraf P，Pecciarini L，et al.PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma[corrected].Science，2000，289（5483）：1357-1360.

100.Gregory Powell J，Wang X，Allard BL，et al.The PAX8/PPARgamma fusion oncoprotein transforms immortalized human thyrocytes through a mechanism probably involving wild-type PPARgamma inhibition.Oncogene，2004，23（20）：3634-3641.

101.Castro P，Rebocho AP，Soares RJ，et al.PAX8-PPARgamma rearrangement is frequently detected in the follicular variant of papillary thyroid carcinoma.J Clin Endocrinol Metab，2006，91（1）：213-220.

102.Adeniran AJ，Zhu Z，Gandhi M，et al.Correlation between genetic alterations and microscopic features，clinicalmanifestations，and prognostic characteristics of thyroid papillary carcinomas.Am JSurg Pathol，2006，30（2）：216-222.

103.Placzkowski KA，Reddi HV，Grebe SK，et al.The Role of the PAX8/PPAR gamma Fusion Oncogene in Thyroid Cancer.PPAR Res，2008，2008：672829.

104.Giordano TJ，Au AY，Kuick R，etal.Delineation，functional validation，and bioinformatic evaluation of gene expression in thyroid follicular carcinomas with the PAX8-PPARG translocation.Clin Cancer Res，2006，12（7 Pt 1）：1983-1993.

105.Melo M，da Rocha AG，Vinagre J，et al.TERT promoter mutations are a major indicator of poor outcome in differentiated thyroid carcinomas.J Clin Endocrinol Metab，2014，99（5）：E754-765.

106.Sun J，Zhang J，Lu J，et al.BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Carcinoma in Chinese Patients.PLoSOne，2016，11（4）：e0153319.

107.Kim NW，Piatyszek MA，Prowse KR，et al.Specific association of human telomerase activity with immortal cells and cancer.Science，1994，266（5193）：2011-2015.

108.Smallridge RC，Marlow LA，Copland JA.Anaplastic thyroid cancer：molecular pathogenesis and emerging therapies.Endocr Relat Cancer，2009，16（1）：17-44.

109.Caronia LM，Phay JE，Shah MH.Role of BRAF in thyroid oncogenesis.Clin Cancer Res，2011，17（24）：7511-7517.

110.Nikiforov YE，Nikiforova MN.Molecular genetics and diagnosis of thyroid cancer.Nat Rev Endocrinol，2011，7（10）：569-580.

111.Jones PA，Baylin SB.The epigenomics of cancer.Cell，2007，128（4）：683-692.

112.Gomez Saez JM.Diagnostic and prognostic markers in differentiated thyroid cancer.Curr Genomics，2011，12（8）：597-608.

113.Jin S，Borkhuu O，BaoW，etal.Signaling Pathways in Thyroid Cancer and Their Therapeutic Implications.J Clin Med Res，2016，8（4）：284-296.

114.White MG，Nagar S，Aschebrook-Kilfoy B，et al.Epigenetic Alterations and Canonical Pathway Disruption in Papillary Thyroid Cancer：A Genome-wide Methylation Analysis.Ann Surg Oncol，2016，23（7）：2302-2309.

115.Ponting CP，Oliver PL，Reik W.Evolution and functions of long noncoding RNAs.Cell，2009，136（4）：629-641.

116.Zaratiegui M，Irvine DV，Martienssen RA.Noncoding RNAs and gene silencing.Cell，2007，128（4）：763-776.

117.Fuziwara CS，Kimura ET.MicroRNA Deregulation in Anaplastic Thyroid Cancer Biology.Int J Endocrinol，2014，2014：743450.

118.Celano M，Rosignolo F，Maggisano V，et al.MicroRNAs as Biomarkers in Thyroid Carcinoma.Int JGenomics，2017，2017：6496570.

119.Yu S，Liu Y，Wang J，et al.CirculatingmicroRNA profiles as potential biomarkers for diagnosis of papillary thyroid carcinoma.J Clin Endocrinol Metab，2012，97（6）：2084-2092.

120.Lee JC，Zhao JT，Clifton-Bligh RJ，et al.MicroRNA-222 and microRNA-146b are tissue and circulating biomarkers of recurrent papillary thyroid cancer.Cancer，2013，119（24）：4358-4365.

121.Cantara S，Pilli T，Sebastiani G，et al.CirculatingmiRNA95 and miRNA190 are sensitive markers for the differential diagnosis of thyroid nodules in a Caucasian population.JClin Endocrinol Metab，2014，99（11）：4190-4198.

122.Graham ME，Hart RD，Douglas S，et al.Serum microRNA profiling to distinguish papillary thyroid cancer from benign thyroid masses.J Otolaryngol Head Neck Surg，2015，44：33.

123.LiM，Song Q，Li H，et al.CirculatingmiR-25-3p and miR-451a May Be Potential Biomarkers for the Diagnosis of Papillary Thyroid Carcinoma.PLoS One，2015，10（7）：e0132403.

124.Lee YS，Lim YS，Lee JC，et al.Differential expression levels of plasma-derived miR-146b and miR-155 in papillary thyroid cancer.Oral Oncol，2015，51（1）：77-83.

125.Samsonov R，Burdakov V，Shtam T，et al.Plasma exosomal miR-21 and miR-181a differentiates follicular from papillary thyroid cancer.Tumour Biol，2016，37（9）：12011-12021.

126.Yu S，Liu X，Zhang Y，etal.CirculatingmicroRNA124-3p，microRNA9-3p and microRNA196b-5p may be potential signatures for differential diagnosis of thyroid nodules.Oncotarget，2016，7（51）：84165-84177.

127.Yoruker EE，Terzioglu D，Teksoz S，et al.MicroRNA Expression Profiles in Papillary Thyroid Carcinoma，Benign Thyroid Nodules and Healthy Controls.JCancer，2016，7（7）：803-809.

128.Rosignolo F，Sponziello M，Giacomelli L，et al.Identification of Thyroid-Associated Serum microRNA Profiles and Their Potential Use in Thyroid Cancer Follow-Up.JEndocr Soc，2017，1（1）：3-13.

129.Zhao JJ，Hao S，Wang LL，et al.Long non-coding RNA ANRIL promotes the invasion andmetastasis of thyroid cancer cells through TGF-beta/Smad signaling pathway.Oncotarget，2016，7（36）：57903-57918.

130.Li JH，Zhang SQ，Qiu XG，et al.Long non-coding RNA NEAT1 promotes malignant progression of thyroid carcinoma by regulatingmiRNA-214.Int JOncol，2017，50（2）：708-716.

131.Kim D，Lee WK，Jeong S，et al.Upregulation of long noncoding RNA LOC100507661 promotes tumor aggressiveness in thyroid cancer.Mol Cell Endocrinol，2016，431.36-45.

132.Li HM，Yang H，Wen DY，et al.Overexpression of LncRNA HOTAIR is Associated with Poor Prognosis in Thyroid Carcinoma：A Study Based on TCGA and GEO Data.Horm Metab Res，2017，49（5）：388-399.

133.Zhu H，Lv Z，An C，et al.Onco-lncRNA HOTAIR and its functional genetic variants in papillary thyroid carcinoma.Sci Rep，2016，6.31969.

134.Liu L，Yang J，Zhu X，et al.Long noncoding RNA H19 competitively binds miR-17-5p to regulate YES1 expression in thyroid cancer.FEBS J，2016，283（12）：2326-2339.

135.Xu B，Shao Q，Xie K，et al.The Long Non-Coding RNA ENST00000537266 and ENST00000426615 Influence Papillary Thyroid Cancer Cell Proliferation and Motility.Cell Physiol Biochem，2016，38（1）：368-378.

136.Zhou Q，Chen J，Feng J，et al.Long noncoding RNA PVT1 modulates thyroid cancer cell proliferation by recruiting EZH2 and regulating thyroid-stimulating hormone receptor（TSHR）.Tumour Biol，2016，37（3）：3105-3113.

137.Li T，Yang XD，Ye CX，et al.Long noncoding RNA HIT000218960 promotes papillary thyroid cancer oncogenesis and tumor progression by upregulating the expression of highmobility group AT-hook 2（HMGA2）gene.Cell Cycle，2017，16（2）：224-231.

138.Sun W，Lan X，Wang Z，et al.Overexpression of long noncoding RNA NR_036575.1 contributes to the proliferation and migration of papillary thyroid cancer.Med Oncol，2016，33（9）：102.

139.Jeong S，Lee J，Kim D，et al.Relationship of Focally Amplified Long Noncoding on Chromosome 1（FAL1）lncRNA with E2F Transcription Factors in Thyroid Cancer.Medicine（Baltimore），2016，95（4）：e2592.

140.Wang Y，Guo Q，Zhao Y，et al.BRAF-activated long noncoding RNA contributes to cell proliferation and activates autophagy in papillary thyroid carcinoma.Oncol Lett，2014，8（5）：1947-1952.

141.Zheng H，Wang M，Jiang L，et al.BRAF-Activated Long Noncoding RNA Modulates Papillary Thyroid Carcinoma Cell Proliferation through Regulating Thyroid Stimulating Hormone Receptor.Cancer Res Treat，2016，48（2）：698-707.

142.He H，Nagy R，Liyanarachchi S，et al.A susceptibility locus for papillary thyroid carcinoma on chromosome 8q24.Cancer Res，2009，69（2）：625-631.

143.Wang C，Yan G，Zhang Y，et al.Long non-coding RNA MEG3 suppresses migration and invasion of thyroid carcinoma by targeting of Rac1.Neoplasma，2015，62（4）：541-549.

144.Yoon H，He H，Nagy R，et al.Identification of a novel noncoding RNA gene，NAMA，that is downregulated in papillary thyroid carcinomawith BRAF mutation and associated with growth arrest.Int JCancer，2007，121（4）：767-775.

145.Wang Y，He H，LiW，et al.MYH9 binds to lncRNA gene PTCSC2 and regulates FOXE1 in the 9q22 thyroid cancer risk locus.Proc Natl Acad Sci U S A，2017，114（3）：474-479.

146.Fan M，Li X，JiangW，etal.A long non-coding RNA，PTCSC3，as a tumor suppressor and a targetof miRNAs in thyroid cancer cells.Exp Ther Med，2013，5（4）：1143-1146.

147.Jendrzejewski J，Thomas A，Liyanarachchi S，et al.PTCSC3 Is Involved in Papillary Thyroid Carcinoma Development by Modulating S100A4 Gene Expression.JClin Endocrinol Metab，2015，100（10）：E1370-1377.

148.Liao T，Qu N，Shi RL，et al.BRAF-activated LncRNA functions as a tumor suppressor in papillary thyroid cancer.Oncotarget，2017，8（1）：238-247.

149.Lan X，Sun W，Zhang P，et al.Downregulation of long noncoding RNA NONHSAT037832 in papillary thyroid carcinoma and its clinical significance.Tumour Biol，2016，37（5）：6117-6123.

150.Ma B，Liao T，Wen D，et al.Long intergenic non-coding RNA 271 is predictive of a poorer prognosis of papillary thyroid cancer.Sci Rep，2016，6：36973.

151.Pan W，Zhou L，Ge M，et al.Whole exome sequencing identifies lncRNAGAS8-AS1 and LPAR4 as novel papillary thyroid carcinoma driver alternations.Hum Mol Genet，2016，25（9）：1875-1884.

152.Wang Q，Yang H，Wu L，et al.Identification of Specific Long Non-Coding RNA Expression：Profile and Analysis of Association with Clinicopathologic Characteristics and BRAF Mutation in Papillary Thyroid Cancer.Thyroid，2016，26（12）：1719-1732.

153.Jenuwein T，Allis CD.Translating the histone code.Science，2001，293（5532）：1074-1080.

154.Kouzarides T.Chromatin modifications and their function.Cell，2007，128（4）：693-705.